Stimulation of Cingulo-opercular Alertness Network

Lewy Body Disease Clinical Trial

— SCAN  

Official title:

Cholinergic Functions and Modulation of the Cingulo-opercular Alertness Network in LBD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04817891
• Other study ID #: HUM00184296
• Secondary ID: R21AG069387
• Status: Completed
• Phase: N/A
• Start date: May 3, 2021
• Est. completion date: August 31, 2023

Study information

• Verified date: December 2023
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fluctuations in alertness are very common in persons with Lewy body dementias and are a major source of disability. Changes in a chemical messenger molecule called acetylcholine within certain brain regions may play a role in these fluctuations. We propose to test this hypothesis and also determine whether a non-invasive way of stimulating affected brain regions may be of relevance for future management of these fluctuations.

Description:

The central premise of the research study is that cholinergic system changes in specific neural network regions underlie cognitive fluctuations in patients with LBD. The cingulo-opercular task control (COTC) neural network is believed to play a role in maintenance of alertness but this remains uncertain in LDB. This critical knowledge gap forms the basis of our first aim. The study proposes to use transcranial direct current stimulation (tDCS) to "excite" critical cholinergic denervation components of the COTC as an adjunct to cholinergic pharmacotherapy in a target engagement study. tDCS is an emerging non-invasive neurostimulation technology that may improve a range of neurological symptoms, including cognition. The study will evaluate whether target engagement by tDCS excitation of cholinergic denervated COTC hubs may affect cognitive fluctuations in LBD subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: August 31, 2023
• Est. primary completion date: August 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 90 Years

Eligibility

Inclusion Criteria:

• LBD patients (DLB or PDD) who have cognitive fluctuations and who are on stable doses of cholinesterase inhibitors (i.e., at least 4 weeks) will be recruited to participate in this study.
• DLB patients will meet the Fourth consensus report of the DLB Consortium inclusion criteria for probable DLB.
• Subjects will be identified according to the following recognized DLB features:

spontaneous parkinsonian motor signs, fluctuating attention and concentration, recurrent well-formed visual hallucinations, presence of REM behavioral sleep disturbance, anosmia/hyposmia,or autonomic dysfunction.

• PDD patients will meet the criteria by Emre et al. (Cognitive deficits in at least two of four of the following cognitive domains: Impaired attention, impaired executive functions, impairment in visuo-spatial functions, impaired free recall memory typically improved with cuing. Must also meet criteria for at least one behavioral symptom: apathy, depressed or anxious mood, hallucinations, delusions, excessive daytime sleepiness). Lack of behavioral symptoms does not exclude the diagnosis. Must also have none of Group III features present: (1) Co-existance of any other abnormality which might cause impairment, but judged not to be the cause of dementia. (2) Time interval between development of motor and cognitive symptoms not known. Must also have none of Group IV symptoms present: (1) Cognitive and behavioral symptoms appear solely in the context of other conditions such as acute confusion caused by systemic diseases or abnormalities, drug intoxication, or major depression according to DSM IV. (2) Features compatible with Probable Vascular Dementia criteria accordingly to NINDS-AIREN.

Exclusion Criteria:

• Subjects with contra-indications to MR imaging and/or tDCS, including pacemakers or claustrophobia
• Evidence of large vessel stroke or mass lesion on MRI
• Use of anti-cholinergic or neuroleptic drugs
• Evidence of atypical parkinsonism on neurological exam
• Major psychiatric illness, such as bipolar disorder
• Neurological conditions such as epilepsy, stroke, multiple sclerosis, or moderate to severe brain injury
• Sensory impairments that significantly limit one's ability to see or hear
• A significant history of recent alcohol or drug dependence
• Previous major radiation exposure
• Pregnancy

Related Conditions & MeSH terms

• Alzheimer Disease
• Dementia
• Lewy Body Dementia With Behavioral Disturbance
• Lewy Body Disease
• Lewy Body Variant of Alzheimer Disease
• Problem Behavior

Intervention

Device:
• HD-tDCS
Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.

Locations

Country	Name	City	State
United States	4251 Plymouth Road (University of Michigan)	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline on Dementia Cognitive Fluctuations Scale	17-item subjective report of cognitive fluctuations, developed to address limitations in prior scales and has good test-retest and inter-rater reliability. Total scores range from 4 to 20, with higher scores indicating greater cognitive fluctuations.	Baseline and Post-Testing (3-4 weeks)
Secondary	Change from Baseline Resting State fMRI	Graph theory analysis or comparable methods will be used to identify changes in cerebral connectivity.	Baseline and Post-Testing (3-4 weeks)